Tumor cell vaccine

BIOLOGICAL2 trials

Sponsors

Hadassah Medical Organization, National Cancer Institute (NCI)

Conditions

Esophageal CancerLung CancerMesoltheliomaMetastatic Solid TumorsThoracic SarcomasThymoma

Phase 1

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

WithdrawnNCT00148993

Hadassah Medical OrganizationMetastatic Solid Tumors

Start: 1998-07-31End: 2005-07-31Target: 100Updated: 2011-04-08

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

TerminatedNCT01258868

National Cancer Institute (NCI)Esophageal Cancer, Lung Cancer, Mesolthelioma +2

Start: 2010-12-01End: 2016-06-13Updated: 2019-12-03